Drugs / GIC-102
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05880043 | Apr 2023 → Dec 2025 | cancer, non-Hodgkin lymphoma, refractory plasma cell neoplasm | GI Cell, Inc. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GIC-102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05880043 ↗ |
| Modality | Cell therapy | “GIC-102 is an "off-the-shelf" allogeneic natural killer cells isolated from non-HLA-related healthy donor.” NCT05880043 ↗ |
| Route | Intravenous | “GIC-102 will be administered via IV infusion 3 times at intervals of 1 week, and 28 days is defined as 1 cycle” NCT05880043 ↗ |